GW Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for Epidiolex®.Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant. Following receipt of this orphan designation, GW anticipates holding a pre-IND meeting with the FDA in the near future to discuss a development plan for Epidiolex in Dravet syndrome.
Info:
www.prnewswire.com/news-releases/gw-pharmaceuticals-provides-update-on-orphan-program-in-childhood-epilepsy-for-epidiolex-232016721.html
Info:
www.prnewswire.com/news-releases/gw-pharmaceuticals-provides-update-on-orphan-program-in-childhood-epilepsy-for-epidiolex-232016721.html
No comments:
Post a Comment